Gluscan

Gluscan is a radiopharmaceutical product containing the active ingredient fludeoxyglucose (18F) supplied as an injectable solution for intravenous administration. It is marketed in the European Union and is prescribed for diagnostic imaging using positron emission tomography (PET). The compound acts as a glucose analog, enabling visualization of metabolic activity in various tissues, which supports clinical assessment in oncology, cardiology, and neurology and research applications worldwide.

Gluscan is employed primarily as a tracer in PET scans to assess glucose metabolism in target organs.

- Oncology: detection, staging, and monitoring of malignant tumors. - Cardiology: evaluation of myocardial viability and perfusion. - Neurology: assessment of cerebral glucose utilization in epilepsy and dementia. - Research: quantification of metabolic activity in clinical trials. - Whole-body imaging: identification of metastatic disease.

Adverse reactions to Gluscan are generally mild, but rare serious events have been reported.

Common: - Transient flushing or warmth at the injection site. - Mild nausea or vomiting. - Short-term headache. - Temporary metallic taste.

Serious: - Severe allergic reaction (anaphylaxis) with rash, bronchospasm, or hypotension. - Significant radiation-induced tissue injury in high-dose exposures. - Persistent vomiting or seizures related to metabolic disturbances.

Use of Gluscan requires careful consideration of patient factors and procedural conditions to ensure safety.

- Verify pregnancy status; avoid use unless benefit outweighs potential fetal radiation risk. - Assess renal function, as impaired clearance may increase radiation exposure. - Ensure fasting for at least 4–6 hours before injection to reduce background glucose uptake. - Review recent administration of other radiopharmaceuticals to avoid cumulative dose. - Monitor for signs of hypersensitivity during and after injection. - Adjust dose in pediatric patients according to body weight and clinical protocol.

Gluscan may interact with other substances that affect glucose metabolism or radiation exposure.

Avoid: - Concurrent use of high-dose iodinated contrast agents immediately before PET, which can alter biodistribution. - Administration of other radiopharmaceuticals within 24 hours, leading to overlapping radiation fields.

Use with caution: - Antidiabetic medications (insulin, oral hypoglycemics) that modify blood glucose levels; glucose should be controlled before imaging. - Chemotherapeutic agents that cause bone‑marrow suppression, potentially affecting tracer uptake. - Corticosteroids, which may influence metabolic activity and PET interpretation.